FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： (註7) (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) 02186 ...

8月20日，绿叶制药(02186)盘中下跌4.02%，截至15:59，报3.82元/股，成交3.02亿元。 绿叶制药集团有限公司主要在全球最大和增长最快的四个治疗领域（肿瘤科、中枢神经系统、心血管系 统及消化与代谢）进行创新药品的开发、生产、推广及销售，产品组合包括超过30种产品，覆盖全球80 个以上国家和地区。关键经营数据显示，2021年，公司产品销售覆盖全国30个省、自治区和直辖市，通 过约1000名销售和营销人员以及约1780家经销商网络，产品销往19330多家医院，同时在国际市场覆盖 80个国家或地区。 本文源自：金融界 作者：行情君 截至2024年年报，绿叶制药营业总收入60.61亿元、净利润4.72亿元。 ...

Core Viewpoint - The company, Green Leaf Pharmaceutical (02186.HK), is set to hold a board meeting on August 28, 2025, to approve its mid-term performance for the six months ending June 30, 2025, and to consider the distribution of an interim dividend, if applicable [1] Related Events - Green Leaf Pharmaceutical plans to hold a board meeting on August 28 to approve mid-term performance [1] - The company has completed patient enrollment for the Phase III clinical trial of Ruxolitinib for the treatment of generalized anxiety disorder in China [1]

綠葉製藥集團有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 LUYE PHARMA GROUP LTD. 綠葉製藥集團有限公司 主 席 劉殿波 香 港，二 零 二 五 年 八 月 十 八 日 於 本 公 告 日 期，本 公 司 執 行 董 事 為 劉 殿 波 先 生、楊 榮 兵 先 生、袁 會 先 先 生 及 祝 媛 媛 女 士；本 公 司 非 執 行 董 事 為 宋 瑞 霖 先 生 及 黃 立 明 先 生；及 本 公 司 獨 立 非 執 行 董 事 為 張 化 橋 先 生、盧 毓 琳 教 授、梁 民 傑 先 生、蔡 思 聰 先 生 及 夏 蓮 女 士。 （於 百 慕 達 註 冊 成 立 之 有 限 公 司） （股 份 代 號：02186） 董事會會議通告 綠葉製藥集團有限公司（「本公司」）董事會（「董事會」）謹 此 宣 佈，本 公 司 將 於 二 零二五年八月二十八日（星 期 四）舉 ...

Group 1 - The core viewpoint of the article highlights the performance and market presence of Green Leaf Pharmaceutical, which saw a stock price increase of 2.89% to 3.91 HKD per share with a trading volume of 302 million HKD on August 18 [1] - Green Leaf Pharmaceutical operates in four major therapeutic areas: oncology, central nervous system, cardiovascular, and digestive and metabolic diseases, focusing on the development, production, promotion, and sales of innovative drugs [1] - The company has a diverse product portfolio with over 30 products, and its sales network includes approximately 1,000 sales and marketing personnel and around 1,780 distributors, reaching over 19,330 hospitals in China and covering more than 80 countries and regions internationally [1] Group 2 - As of the 2024 annual report, Green Leaf Pharmaceutical reported total revenue of 6.061 billion CNY and a net profit of 472 million CNY [1]

Group 1 - The core point of the news is that Green Leaf Pharmaceutical has completed patient enrollment for the Phase III clinical trial of its innovative drug, Ruoxinlin, aimed at treating generalized anxiety disorder (GAD) [1] - The Phase III trial is a multi-center, randomized, double-blind, placebo-controlled study involving 555 patients, with the primary endpoint being the change in Hamilton Anxiety Scale (HAM-A) scores at the end of week 8 [1] - The company expects to complete the clinical trial by the end of this year and submit a marketing application for this indication [1] Group 2 - Generalized anxiety disorder is the most common mental disorder in China, affecting approximately 53.1 million people as of 2021 [1] - There have been no innovative drugs approved for the treatment of anxiety disorders globally in the past 15 years, making Ruoxinlin a potential first-in-class serotonin, norepinephrine, and dopamine reuptake inhibitor (SNDRI) for GAD [1] Group 3 - Ruoxinlin is the first independently developed innovative drug in China for treating depression, having been approved in 2022, and has shown significant clinical efficacy and safety [3] - The drug has been recognized for its ability to improve depressive symptoms without causing insomnia, sedation, or affecting sexual function, weight, and lipid metabolism [3] - Ruoxinlin has served over 80,000 patients since its launch and is the fastest-growing antidepressant in China [3] Group 4 - The demand for treatments in the central nervous system field, including depression and anxiety, is substantial, but new drug development has been relatively slow [4] - The company has received approvals for a series of competitive innovative drugs in various markets, including the US, Europe, and Japan [4] - The company is actively developing next-generation innovative drugs, with several first-class innovative drugs in clinical stages targeting multiple receptors [4]

Group 1 - The core point of the news is that Green Leaf Pharmaceutical (02186.HK) has completed patient enrollment for its Phase III clinical trial of the innovative drug Ruoxinlin® (Toralacitinib) for treating Generalized Anxiety Disorder (GAD) [1] - The Phase III trial is a multi-center, randomized, double-blind, placebo-controlled study involving 555 patients, with the primary endpoint being the change in Hamilton Anxiety Scale (HAM-A) scores from baseline at week 8 [1] - The company expects to complete the clinical trial by the end of this year and submit a marketing application for this indication [1] Group 2 - Generalized Anxiety Disorder is the most common mental disorder in China, affecting approximately 53.1 million people as of 2021, with a long duration and high recurrence rate impacting patients' quality of life [1] - Ruoxinlin® is expected to be the first drug globally approved for treating GAD that acts as a triple reuptake inhibitor of serotonin (5-HT), norepinephrine (NE), and dopamine (DA) [1] - Current first-line treatments for GAD include SSRIs and SNRIs, which have common side effects leading to low patient compliance and treatment discontinuation [2] Group 3 - Ruoxinlin® is the first domestically developed innovative drug for treating depression in China, having been approved for market since 2022, and has shown efficacy and safety in clinical settings [2] - Clinical trials have demonstrated that Ruoxinlin® significantly improves depression symptoms without causing insomnia, sedation, or affecting sexual function, weight, and lipid metabolism [2] - The drug also shows potential anxiolytic effects, improving HAM-A scores and other anxiety-related measures while providing antidepressant benefits [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 的全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 LUYE PHARMA GROUP LTD. 綠葉製藥集團有限公司 （於 百 慕 達 註 冊 成 立 之 有 限 公 司） （股 份 代 號：02186） 自願性公告 若欣林®治療廣泛性焦慮障礙的 中國Ⅲ期臨床試驗完成所有患者入組 綠葉製藥集團 有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）董事會（「董 事 會」）宣 佈，本 集 團 自 主 研 發 的1類創新藥若欣林® （鹽 酸 托 魯 地 文 拉 法 辛 緩 釋 片）用 於 治 療 廣 泛 性 焦 慮 障 礙 的 Ⅲ 期 臨 床 試 驗 已 完 成 所 有 患 者 入 組。 該 項 Ⅲ 期 臨 床 試 驗 為 一 項 多 中 心、隨 機、雙 盲、安 慰 劑 對 照 的 研 究，以 評 估 若 欣 林®治 療 廣 泛 性 焦 慮 障 礙 的 安 全 性 和 有 效 性。試 ...

Core Insights - The top three companies with the highest short positions as of August 8 are WuXi AppTec (17.83%), CATL (14.76%), and COSCO Shipping Holdings (13.33%) [1][2] - The companies with the largest absolute increase in short positions are Hutchison China MediTech (2.12%), Yangtze Optical Fibre and Cable (1.78%), and Ming Yuan Cloud (1.77%) [1][2] - The companies with the largest absolute decrease in short positions are WuXi AppTec (-3.16%), BYD (-1.38%), and Hua Hong Semiconductor (-0.99%) [1][3] Top Short Positions - The top ten companies with the highest short positions include: - WuXi AppTec: 82.73 million shares, 17.83% - CATL: 23.01 million shares, 14.76% - COSCO Shipping Holdings: 384 million shares, 13.33% - Ganfeng Lithium: 53.76 million shares, 13.32% - Green Leaf Pharmaceutical: 503 million shares, 13.11% - Vanke: 280 million shares, 12.68% - Fuyao Glass: 55.51 million shares, 12.57% - Ping An Insurance: 908 million shares, 12.19% - MicroPort Medical: 22.2 million shares, 11.65% - Tigermed: 14.00 million shares, 11.38% [2] Increase in Short Positions - The companies with the largest increase in short positions are: - Hutchison China MediTech: increased from 3.36% to 5.48%, a change of 2.12% - Yangtze Optical Fibre and Cable: increased from 6.01% to 7.78%, a change of 1.78% - Ming Yuan Cloud: increased from 3.04% to 4.82%, a change of 1.77% - China Resources Medical: increased from 3.10% to 4.51%, a change of 1.41% - ZhongAn Online: increased from 6.56% to 7.55%, a change of 1.00% [2] Decrease in Short Positions - The companies with the largest decrease in short positions are: - WuXi AppTec: decreased from 20.99% to 17.83%, a change of -3.16% - BYD: decreased from 8.01% to 6.63%, a change of -1.38% - Hua Hong Semiconductor: decreased from 9.48% to 8.48%, a change of -0.99% - Shanghai Electric: decreased from 3.25% to 2.31%, a change of -0.94% - China National Pharmaceutical: decreased from 6.37% to 5.43%, a change of -0.94% [3][4]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 绿叶制药集团有限公司 呈交日期： 2025年8月14日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) 02186 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件 ...